Grant Details
Grant Number: |
1R03CA078425-01 Interpret this number |
Primary Investigator: |
Cheng, Lie |
Organization: |
University Of Texas Md Anderson Can Ctr |
Project Title: |
Ner Gene Expression in Head and Neck Cancer |
Fiscal Year: |
1998 |
Abstract
DESCRIPTION: (Applicant's Description) The fact that only about 15 percent
of smokers will develop lung cancer in their lifetime suggests a genetic
susceptibility to tobacco-related cancers. This inherited variation in
susceptibility may be partly due to genetically determined variation in DNA
repair capacity that influences the rate of DNA damage removal and fixation
of mutations. Although many risk factors are similar in lung cancer and
head and neck cancer (HNC), others such as alcohol use are unique in HN
cancer. While mutations occurring in genes involved in signal transduction,
regulation of gene expression, and cellular proliferation may be responsible
for tumor initiation, genetic changes in DNA repair genes may be even
earlier events in tumorigenesis. The well-studied smoking-related
carcinogen benzo[a]pyrene induces damage to cellular DNA primarily through
adducts formed by its metabolite, benzo[a]pyrene diol epoxide (BPDE), an
ultimate carcinogen. These DNA adducts are repaired by a
nucleotide-excision repair (NER) pathway that is responsible for the
restoration of normal DNA structure. It is conceivable that baseline level
of transcript of DNA repair gene reflects cellular ability to meet repair
demand once the cells are stimulated by carcinogen exposure. Although
reduced DNA repair capacity has been shown to be associated with
smoking-related cancer such as lung cancer, few studies have been conducted
to evaluate the role of DNA repair in the etiology of HNC. We hypothesize
that genetically determined alteration in the baseline expression of genes
involved in NER is associated with risk of head and neck cancer. In this
pilot study, we propose to test our hypothesis in a pilot study of 75 cases
with head and neck cancer and 75 controls without cancer. We will determine
differences of the relative expression levels of five NER genes (ERCC1,
ERCC3, ERCC5, ERCC6 and XPC) in phytohemagglutinin-stimulated peripheral
lymphocytes of patients with head and neck cancers and controls without
cancer. We will also determine the association between the relative
expression levels of NER genes and the risk of head and neck cancers with
adjustment for other known epidemiologic risk factors such as smoking and
alcohol use, which may have an effect on the baseline expression. The
results of this pilot study may help validate the usefulness of this new
RT-PCR assay in large scale epidemiologic studies in the future.
Publications
None